Inozyme Pharma Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Inozyme Pharma şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-6.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-6.4%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Jul 19

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Jul 12

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Apr 06

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Dec 22

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Sep 08

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

May 22

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

May 07

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Feb 06

Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder

Jan 04

Inozyme Pharma (INZY) Investor Presentation - Slideshow

Dec 03

Inozyme Pharma EPS misses by $1.02

Nov 12

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: INZY şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: INZY şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Inozyme Pharma Piyasaya Karşı Temettü Getirisi

INZY temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (INZY)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (INZY) (3 yıla kadar)	0%

Önemli Temettü: INZY şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, INZY şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: INZY şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: INZY herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Inozyme Pharma Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc. Announces Positive Interim Data from Phase 1 Seaport 1 Trial of INZ-701

Inozyme Pharma, Inc. Announces Appointment of Erik Harris to its Board of Directors

New major risk - Financial position

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?

Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion

Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency

New major risk - Revenue and earnings growth

Price target decreased by 7.5% to US$19.43

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc., Annual General Meeting, Jun 18, 2024

Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?

Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency (PXE) and ENPP1 Deficiency

CEO & Chairman exercised options and sold US$52k worth of stock

New minor risk - Share price stability

Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency

New major risk - Revenue and earnings growth

Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy in Genomics England's Generation Study of Rare Conditions

Inozyme Pharma, Inc. Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

New minor risk - Share price stability

Price target decreased by 9.3% to US$20.50

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Inozyme Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Price target increased by 8.5% to US$22.60

Inozyme Pharma, Inc. Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in Phase 1b Trial of INZ-701

Insufficient new directors

Price target decreased by 13% to US$19.17

Inozyme Pharma, Inc. Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701

Price target increased by 8.5% to US$21.80

Inozyme Pharma, Inc. Provides Business Updates

Inozyme Pharma, Inc. Announces First Self-Administration of Inz-701 in Ongoing Enpp1 Deficiency Phase 1/2 Clinical Trial

Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database

Price target increased to US$23.20

Inozyme Pharma GAAP EPS of -$0.38

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Subjects with ABCC6 Deficiency (pseudoxanthoma elasticum or PXE)

Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency

Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Index

Inozyme Pharma, Inc. Appoints Kurt Gunter as Chief Medical Officer

Price target decreased to US$29.40

Inozyme Pharma, Inc. Provides Update for Phase 1/2 Clinical Trials in ABCC6 Deficiency and ENPP1 Deficiency

We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Inozyme Pharma, Inc. Announces Positive Preliminary Data from Phase 1/2 Clinical Trial of INZ-701 in Patients with ENPP1 Deficiency

Price target decreased to US$30.00

Inozyme Pharma, Inc. Announces Management Changes

High number of new directors

Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation

Price target decreased to US$32.25

Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth

Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency

Inozyme Pharma, Inc.(NasdaqGS:INZY) dropped from Russell 2500 Growth Index

President exercised options and sold US$65k worth of stock

Inozyme Pharma, Inc. Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of Inz-701 in Abcc6 Deficiency

We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate

Senior Vice President of Finance Stephen Basso has left the company

Inozyme Pharma, Inc. Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency

Member of Scientific Advisory Board has left the company

Member of Scientific Advisory Board has left the company

Member of Scientific Advisory Board has left the company

New 90-day low: US$19.96

We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely

Inozyme Pharma Announces Executive Changes

Senior VP & Chief Medical Officer has left the company

New 90-day high: US$27.90

Inozyme Pharma, Inc. Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 Deficiency

Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder

Inozyme Pharma (INZY) Investor Presentation - Slideshow

Inozyme Pharma EPS misses by $1.02

Inozyme Pharma Appoints Kevin B. Johnson as Senior Vice President, Regulatory Affairs